Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Surgical treatment of the neck in patients with salivary gland carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Prognostic scoring models in parotid gland carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Outcome in patients with isolated regional recurrence after primary radiotherapy for head and neck cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prognostic scoring models in parotid gland carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Manuscript title: the maxillary swing approach - the first Scandinavian experience

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sinonasal cancer in Denmark 2008-2015: a population-based phase-4 cohort study from DAHANCA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Elective neck dissection (END) in patients with salivary gland carcinoma is controversial and there are no universally accepted guidelines.

METHODS: Patients were identified from the Danish Head and Neck Cancer Group. Between 2006 and 2015, 259 patients with primary salivary gland carcinoma were treated with END. Variables potentially associated with regional metastases were analyzed using logistic regression. Neck recurrence-free survival was calculated using the Kaplan-Meier method.

RESULTS: Occult metastases were found in 36 of the patients treated with END (14%) and were particularly frequent among patients with T3/T4 tumors and high-grade histology tumors. In multivariate analyses, high-grade histology and vascular invasion were associated with occult metastases.

CONCLUSION: We recommend END of levels II and III for patients with high-grade or unknown histological grade tumors, and for T3/T4 tumors. Levels I, II, and III should be included in END in patients with submandibular, sublingual, or minor salivary gland carcinomas.

OriginalsprogEngelsk
TidsskriftHead and Neck
Vol/bind43
Udgave nummer6
Sider (fra-til)1898-1911
Antal sider14
ISSN1043-3074
DOI
StatusUdgivet - jun. 2021

ID: 65606776